Nov 2018
A SYSTEMATIC REVIEW OF EFFECTIVENESS OF MEDICINAL CANNABIS FOR PSYCHIATRIC, MOVEMENT AND NEURODEGENERATIVE DISORDERS.
Keane Lim, Yuen Mei See & Jimmy Lee
Clin Psychopharmacol Neurosci. 2017 Nov; 15(4): 301-312
Published online 2017 Nov. 30 Doi: [10.9758/cpn.2017.15.4.301].
The review of 24 reports evaluates the use of medicinal cannabis for psychiatric, movement and neurodegenerative disorders including; Alzheimer’s disease, anorexia nervosa, anxiety, dementia, dystonia, Huntington’s disease, Parkinson’s disease, post-traumatic stress disorder (PTSD), psychosis and Tourette syndrome. The available evidences suggest there is a potential benefit of cannabinoids for those diseases however further research is required to confirm its efficacy.
Pre-clinical studies documenting the anti-cancer effects of THC and its success in inhibiting cancer growth and spread have been on the rise. Clinical studies however are scarce as the psychoactive effects of THC can limit its medicinal and clinical use. Could non-psychoactive cannabinoids found in cannabis and hemp be the answer to treating cancer instead?
At ANTG, we are uniquely well-positioned to supply the domestic market and become the first medicinal cannabis company in Australia to export cannabis flower for commercial purposes to the EU. Interested in investing in medicinal cannabis? Read what sets ANTG apart.